Vasoactive intestinal peptide (VIP) is an important growth regulator of the embryonic day (E)9 -E11 mouse. In comparably aged rat embryos, VIP messenger RNA (mRNA) is not detectable; however, peak concentrations of VIP in maternal rat serum indicate a nonembryonic source. In the current study, mouse maternal and embryonic tissues were examined from E6 -E12. Although RT-PCR revealed VIP mRNA in E6 -E7 conceptuses, by E8 (when extraembryonic tissues could be separated from the embryo), VIP mRNA was detected only in the decidua/trophoblast. Decidual/trophoblastic VIP mRNA decreased until E10, after which it was not detectable. VIP mRNA was not apparent in the embryo until E11-E12. At E9, VIP immunoreactivity was localized to abundant, diffuse cells in the decidua basalis, which were also immunoreactive for T cell markers. VIP binding sites were dense in the decidua/trophoblast at E6, but gradually decreased until E10, after which they were not apparent. VIP binding sites were detected in embryonic neuroepithelium by E9. The transient presence of VIP binding sites and mRNA in the decidua/trophoblast correlate with the critical period of VIP growth regulation, when VIP mRNA is absent in the embryo. These findings suggest that maternal lymphocytes are the source of VIP's regulating early postimplantation embryonic growth. (Endocrinology 140: [917][918][919][920][921][922][923][924] 1999) 
T HE NEUROTROPHIC vasoactive intestinal peptide
(VIP) is an important regulator of embryonic growth during the early postimplantation period, embryonic days (E)9 -E11 in the mouse. VIP treatment of whole mouse embryo cultures at E9.5 significantly augmented embryonic growth and development. A 4-h treatment with VIP resulted in significant increases in somite number, DNA, protein, and cross-sectional area (1) . In addition, treatment of pregnant mice with a VIP antagonist from E9.5-E11.5 produced growth restriction and microcephaly in the pups. However, treatment with the VIP antagonist after E11.5 did not result in gestational growth abnormalities, suggesting that VIP regulation of growth is limited to a specific time period post implantation (2) . Critical developmental events occur at this time of embryogenesis, including neural tube closure, organogenesis, and the conversion from yolk sac to placental nutrition. In the embryo, VIP seems to act through binding sites that are primarily, if not exclusively, restricted to the floor plate and adjacent neuroepithelium of the developing nervous system (3, 4) . VIP treatment down-regulated embryonic VIP binding sites of cultured embryos (1) , and treatment with a VIP antagonist up-regulated embryonic binding sites (2) .
During this critical time period post implantation, there is a maternal response to the developing embryo, resulting in an infiltration of lymphocytes into the decidua (5). The decidual cellular milieu at this time period is mixed and includes lymphocytes, natural killer cells, and macrophages (6) . However, one specific subtype of lymphocyte, with a ␥␦ T cell receptor, is abundant and disproportionally high, compared with circulating levels (7) . These ␥␦ lymphocytes are thought to have a specific role in the maternal-fetal interaction (7) . Lymphocytes are known to express VIP messenger RNA (mRNA) (8) and have VIP receptors (9, 10) .
The purpose of the current study was to characterize VIP mRNA, VIP peptide, and VIP binding sites in E6 -E12 mouse embryos and extraembryonic tissues, identifying potential sources of VIP for growth regulation at this critical time.
Materials and Methods

Gestational days
Because VIP is an important regulator of embryonic growth between E9 -E11 of the mouse, we studied VIP mRNA, maternal plasma VIP, and VIP binding sites between days E6 -E12. Mice at E9 and E17 were used to evaluate maternal organ and embryonic VIP levels. E17 was chosen as a time point beyond the known effects of VIP on embryonic growth. pliance with the Guideline for Care and Use of Experimental Animals. Six-week-old females (21-24 g ) were mated with NIH Swiss males for 4 h. The presence of a vaginal plug was considered day zero of pregnancy.
RT-PCR
On days 6 -12 of pregnancy, conceptuses (embryo and membranes) and decidua were explanted from the uterus and placed in PBS. At E6 and E7, when structures were too small to clearly dissect apart microscopically, conceptuses were analyzed without dissection and contained the embryo proper, membranes, trophoblast, and surrounding decidua. From E8 -E12, when the embryo could be dissected away from the extraembryonic membranes and decidua (with adhering trophoblast, i.e. decidua/trophoblast), these three issues were analyzed separately. At E11-E12, the placentas were easily identified as separate structures and were analyzed separately. Quantitative RT-PCR was performed on the decidua, and samples were taken from that portion of the decidua immediately adjacent to the uterine wall, for each gestational day from E6 -E17. All tissues were thoroughly rinsed in PBS and placed in 0.5 ml RNA STAT-60 (Tel-Test, Inc., Friendswood, TX), with tissues from a minimum of three different conceptuses pooled in each sample and a minimum of three samples studied per developmental age. The tissues were homogenized in RNA STAT-60, using disposable micropestles to avoid cross-contamination, and were stored at Ϫ80 C. In addition, fetal brains from gestational day 17 mice were removed, homogenized in RNA STAT-60, and stored at Ϫ80 C.
For RNA extraction, samples were thawed on ice, 0.1 ml chloroform was added, and they were vortexed and allowed to sit on ice for 5 min. The samples were centrifuged in a microcentrifuge for 15 min at 4 C. Supernatants were transferred to clean tubes, and 0.3 ml isopropanol was added to each; samples were vortexed and frozen on dry ice for 30 min. After thawing on ice, samples were centrifuged, as before, at 4 C. Pellets were washed three times with 75% ethanol, air-dried, and resuspended in 50 l DEPC-treated water. A 5-l aliquot was taken for spectrophotometric determination of RNA content. The remaining sample was stored at Ϫ80 C.
Using 5 g of total RNA, the RT reaction was performed with reverse transcriptase (Perkin-Elmer Corp., Branchburg, NJ), as recommended by the manufacturer, in a final vol of 150 l. Each RNA sample, which was a pooled sample of at least three conceptuses, was run in duplicate. Negative controls included RT reactions performed, omitting RNA or reverse transcriptase. Each PCR reaction was repeated at least twice with different samples of the RT reaction product. Primer pairs and their mimics were designed using Oligo software (National Biosources Inc., Plymouth, MN) and were synthesized (Bio-Synthesis, Inc., Louisville, TX).
The VIP primer pair used were 5Ј-CAG GAA CCG GGA ACA GAC T (sense) and 5Ј-TAT CAG GAA TGC CAG GAA CT (antisense). Negative controls included omission of the template in the PCR reaction. A positive control was derived from tissue samples of mouse cortex that exhibited a VIP mRNA band at 20 -25 PCR cycles. The negative control was E17 mouse tail RNA. Tail RNA exhibited an amplification product at 35-40 PCR cycles. Cycle tests for cortex and E17 tail were run in each PCR experiment to determine when VIP became positive.
Specifically, replicate cortex samples were removed at cycles 20, 25, 28, and 30; replicate tail samples were removed at cycles 28, 30, 35, and 40. In each experiment, there was at least a ten-cycle difference between the appearance of VIP amplification product in the positive and negative controls. Thirty cycles was designated as the negative cutoff for detection of VIP mRNA in the unknown samples. Negative controls were run at 30 and 40 cycles. Interexperiment controls included aliquots from the same sample of adult cortex and E17 tail in each series of RT reactions. Samples were also run with cyclophilin primers as an internal control for each reaction and for use for qualitative comparisons between the samples. The amplification reactions were run on 4 -20% acrylamide TBE gels (Novex, San Diego, CA). Gels were stained with 0.01% ethidium bromide for 10 min and photographed.
Quantitation of mRNA
cDNA mimics with the desired sequence and an internal deletion were constructed using PCR amplification of mouse cortex cDNA, isolated as described, using a 5Ј primer homologous to two regions of the desired gene sequences along with the appropriate 3Ј sequence. The 5Ј deletion primers for cyclophilin were 5Ј-ATG GCA CAG GAG GAA AGA GCA ATG CAG GCA AAG ACA CC; and for VIP, 5Ј-CAG GAA CCG GGA ACA GAC TAG CCG GAA AGG CAG CCC TG. Products obtained from the synthesis were run on a 2% agarose gel (3 g Nusieve, 1 g agarose, 200 ml of 1 ϫ TBE with 10 l ethidium bromide) in 1 ϫ TBE with 10 l ethidium bromide. Bands of the appropriate molecular weight were collected into prepared Na 45 diethylaminoethyl membranes from Schleicher & Schuell, Inc. The membranes were treated with 100 l high-salt NET buffer (1 m NaCl, 0.1 mm EDTA, 20 mm Tris, pH 8) and incubated at 55 C for 10 min. The buffer was removed and saved; this step was repeated for a total of three times (300 l total). This was extracted three times with 300 l water-saturated n-butanol, precipitated with 900 l of 95% ethyl alcohol, and washed three times in 75% ethanol.
For quantitation of mRNA, the PCR reaction was run with dilutions of mimic primers (2 l), with incorporation of 32 P-deoxy-ATP. Each sample was also run with dilutions of a cyclophilin mimic, for internal normalization. To prevent evaporation, each sample was overlaid with 2 drops of mineral oil. The amplification reactions were separated through a 4 -20% acrylamide Tris-borate EDTA gel (Novex). Gel-Marker (Research Genetics, Inc., Huntsville, AL) was run on each gel as a marker for determination of band size. Gels were stained with 0.01% ethidium bromide for 10 min and photographed, dried (Bio-Rad Laboratories, Inc., Richmond, CA), and placed on 3 m Whatman paper (Whatman International Ltd., Maidstone, UK). The gels were exposed to a Molecular Dynamics, Inc. (Sunnyvale, CA) storage phosphor screen for 18 -24 h. Using ImageQuant software (Molecular Dynamics, Inc.), band intensities were measured. The location of the cross-over, from predominately mimic product to message product, was calculated after phosphoimage analysis. The samples were normalized to the cyclophilin cross-over. The cross-over values from each gestational day were compared with gestational day 17 and were expressed as the percentage of gestational day 17.
Enzyme-linked immunosorbent assay (ELISA)
At gestational days 9 and 17, conceptuses were explanted from the uterus, within decidua (embryo, membranes, trophoblast, decidua, and fluid), and maternal organs were removed (ovary, uterus, cervix/paracervix, intestine, cortex, hypothalamus, spinal cord, and placenta) from at least five different pregnant mice. These were quick-frozen on dry ice and stored at Ϫ80 C. The tissue was weighted and homogenized in 3 ml of 0.1 N HCl. Samples were vortexed, placed in boiling water for 10 min, cooled on ice, vortexed, and centrifuged at 10,000 ϫ g for 30 min. One-milliliter aliquots were evaporated to dryness in vacuo. Dried samples were stored at Ϫ80 C.
For the E6 -E12 plasma samples, blood was collected by cardiac puncture into a syringe containing 15% EDTA and aprotinin (ICN Biomedicals, Inc., Aurora, OH). The samples were centrifuged at 1,600 ϫ g for 10 min. The plasma from at least three mice was pooled, frozen on dry ice, and kept at Ϫ80 C until used. Using 0.5 ml of plasma for each gestational day, plasma extraction was performed using Sep-Pack columns, according to the manufacturer's protocol, with 1.0% trifluoroacetic acid (HPLC grade), and eluted with 3 ml of a 60% acetonitrile (HPLC grade), 1% trifluoroacetic acid. The eluate was collected in a polypropylene tube, triturated, and divided into two polypropylene tubes. The samples were evaporated to dryness, under vacuum, and stored at Ϫ80 C until the ELISA was performed. Protein determination (Bio-Rad protein assay; Bio-Rad Laboratories, Inc., Hercules, CA) was performed on each sample before the ELISA. For the ELISA (Peninsula Laboratories, Inc., Belmont, CA), 10 mg/well of protein was added from each sample. The specificity of the ELISA is 100% for VIP (human, porcine, rat, and guinea pig) and for VIP 10 -28 (human, porcine, and rat). The ELISA specificity for VIP from chicken is less than 1%; and for pituitary adenylate cyclase-activating polypeptide (PACAP)-27 (human, ovine, and rat), it is less than 0.02%. The ELISA has no cross-reactivity with substance P, endothelin-1, secretin, glucagon, galanin, somatostatin, or PACAP-38 (human, ovine, and rat). The linear range of the ELISA for VIP is 0.04 -2.0 ng/ml. Concentrations of VIP were calculated per mg protein for maternal organs or per ml for maternal plasma samples. The interassay and intraassay coefficients of variation for the VIP ELISA were 4% and 8%, respectively.
Collection of human serum
Women in early gestation, at a maximum of 5 weeks from their last menstrual period, were identified in the Obstetrics clinic at William Beaumont Army Medical Center. Gestational dating was confirmed in the 25 women who met this criteria (using transvaginal sonography, at the initial visit and weekly thereafter, until 6 weeks post conception). Seven milliliters of blood was collected in a tube containing EDTA and aprotinin. The sample was immediately centrifuged, and the obtained plasma was stored in a Ϫ80 C freezer until the assay was run. An average of 5.5 samples were obtained from each patient, with a range of 2-7.
RIA for VIP in maternal (human) serum samples was performed by Covance Laboratories, Inc. (Vienna, VA) with the use of a 125 I-RIA kit (INCSTAR Corp., Stillwater, MN). Sensitivity of the RIA was 5 pg/ml. For specificity, cross-reactivity was found to be less than 0.1%, with secretin and 15 other peptides.
Immunocytochemistry (ICC)
Uteri from E9 gestations were fixed in situ with 4% paraformaldehyde, removed, and quick-frozen on dry ice. Twenty-micron sections were cut on a cryostat and mounted on slides. For fluorescent ICC, sections were fixed in cold acetone for 10 min, at 4 C, on a shaker. After rinsing, the slides were incubated in 5% donkey serum (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) in PBS, at room temperature for 45 min, to suppress nonspecific binding of IgG. The slides were incubated with the primary antibody overnight [anti-VIP, 1:500 (INCSTAR Corp.), and anti-CD3-⑀ (Santa Cruz Biotechnology, Inc., Santa Cruz, CA)]. Anti-VIP is a rabbit antisera; anti-CD3-⑀ is an affinitypurified goat polyclonal antibody to CD3-⑀, which is present on T lymphocytes. The slides were then incubated in 5% donkey serum/PBS for 45 min. To permit identification of colocalized antigens, the sections were then incubated, in the dark, in the fluorescein-conjugated secondary antibody [lissamine rhodamine-conjugated AffiniPure donkey antirabbit IgG for VIP, 1:200; and CY2-conjugated AffiniPure donkey antigoat IgG for CD3, 1:100 (both from Jackson ImmunoResearch Laboratories, Inc.)] for 45 min.
After incubation, the sections were washed, mounted in 90% glycerol/PBS, and examined with a fluorescence microscope. For standard ICC, the sections were pretreated with 3% H 2 O 2 to deactivate any endogenous peroxidase activity, blocked in 1% BSA for 1 h, and then incubated with goat polyclonal IgG anti-T cell receptor ␦, 1:50 (Santa Cruz Biotechnology, Inc.), at 4 C, overnight. After washing, slides were incubated with rabbit antigoat IgG, 1:2000 (Vectastain, Vector Laboratories, Inc., Burlingham, CA), for 1 h. The sections were reacted by using the ABC method and visualized by 3,3Ј-diaminobenzidine (Sigma Chemical Co., St. Louis, MO). For dual labeling, after washing, the slides were blocked in 1% BSA for 30 min and incubated with the second primary antibody, rabbit anti-VIP, 1:500 (INCSTAR Corp.), at 4 C, overnight. After washing, slides were incubated with goat antirabbit, 1:2000 (Vectastain, Vector Laboratories, Inc.), for 1 h. The sections were reacted by using the conventional ABC method and visualized with Vector VIP, a peroxidase substrate kit (Vectastain, Vector Laboratories, Inc.), which stained the immunoreactive areas purple. The slides were then dehydrated and coverslipped. The specificity of the antiserum was examined, by soluble preadsorption with the peptides in question, at a final concentration of 10 Ϫ5 m (INCSTAR Corp.). VIP immunolabeling was completely abolished by preadsorption with VIP. Preadsorption with the following peptides resulted in no reduction of immunostaining: (PACAP-38), secretin, gastric inhibitory polypeptide, somatostatin, glucagon, insulin, ACTH, gastrin 34, FMFR-amide, rat GHRF, human GHRF, peptide histidine isoleucine 27, rat pancreatic polypeptide, motilin, peptide YY, substance P, neuropeptide Y, and CGRP.
In vitro autoradiography
To identify VIP binding sites, in vitro autoradiography with 125 I-VIP was performed as described previously (3, 11) . In summary, a minimum of eight uteri per E were sectioned, at 20 m, on a cryostat, and were dried and frozen at Ϫ80 C until use. The slides were brought to room temperature and preincubated in binding buffer (10 
Results
VIP mRNA
In the E6 and E7 conceptions, which were evaluated intact (with extraembryonic membranes, decidua, and trophoblast), RT-PCR detected VIP message (data not shown). In E8 -E10 embryonic tissues (which could be separated into embryo proper, decidua/trophoblast, and extraembryonic membranes), VIP mRNA was detected only in the decidua/ trophoblast (Fig. 1) . By E11 or E12, VIP mRNA was no longer evident in the decidua/trophoblast but was detected in the embryo proper (Fig. 1) . VIP mRNA was not detectable in the extraembryonic membranes (E8 -E12), E9 yolk sac, or in the placenta (E11-E12) (data not shown). RT-PCR detected VIP mRNA in E17 fetal brains (Fig. 1 ). All PCR reactions had comparable cyclophilin products (data not shown).
Quantitative RT-PCR of the decidual samples revealed increased VIP mRNA in the early postimplantation decidua, compared with later in gestation, with a peak at E6 -E8 (Fig. 2) .
FIG. 1. RT-PCR of VIP mRNA in E8 -
E12 of mouse embryo and decidua/trophoblast, E6 -E12 decidua, and E17 fetal brain. VIP mRNA is present at E11-E12 embryo and E6 -E10 decidua/ trophoblast, and E17 brain, all at 30 cycles. Adult cortex (AC) and E17 tail (Tail) were positive and negative controls. Internal controls, RNA omitted in RT reaction (-RNA) and RT product omitted in the PCR reaction (-RTP), were run at 40 cycles. EB, E17 brain Peptide VIP immunoreactivity was detected by ELISA in E9 conceptuses (embryo proper, extraembryonic membranes, amniotic fluid, trophoblast, and decidua) and was significantly elevated, compared with E17 conceptuses (15.8 Ϯ 0.8 vs. 7.5 Ϯ 1.7 ng/mg protein, P Ͻ 0.01). There were no significant differences in material organ concentrations of VIP between gestational days 9 and 17 (Fig. 3) . Maternal intestine and cortex had the highest VIP levels among the organs tested. Some of the maternal organs' VIP concentrations were below the detection of the ELISA. For gestational day 9, 1/6 uteri and 4/12 cervix/paracervix were below the limit of detection. For gestational day 17, 1/5 ovaries and 1/5 spinal cords were below the detection of the ELISA. Maternal plasma levels of VIP did not vary significantly throughout gestational days 6 -12 (Fig. 4) . All plasma samples were within the detection limits of the ELISA.
Although women were assessed at a maximum of 21 days post conception, no clear pattern was evident for an elevation in VIP serum levels during the 6 weeks the women were studied. Though it is possible that a narrow peak was missed, because of the weekly interval that the women were studied, these data are consistent with and complement those obtained by Ottesen et al. (12) , who collected plasma from 14 weeks' gestation.
VIP immunoreactivity was present in numerous scattered small cells throughout the decidua. Fluorescent-ICC revealed VIP immunoreactivity in decidual cells that colocalized with cells immunoreactive for the CD3 T cell receptor (Fig. 5) . In addition, ICC demonstrated VIP immunoreactivity in cells of the decidua that colocalized with cells immunoreactive for the TCR ␦ receptor (Fig. 6 ).
Binding sites
Beginning at E6, VIP binding sites were abundant in the mesometrial stroma, which was undergoing decidualization, and remained dense through E7 and E8 (Fig. 7) . By E9, decidual binding sites were much less apparent; and after E10, they were not evident. In the embryo, VIP binding sites were abundant in the floor plate and adjacent neuroepithelium from E9, the earliest age at which the neural tube was easily identified on autoradiograms (Fig. 7) . In the mesometrial stroma, which was undergoing decidualization, most of the VIP binding was GTP-sensitive and completely displaced by GTP (Fig. 8) ; however, most binding in the interimplantation uterus seemed to be insensitive to GTP (Fig. 8-middle) . A small region with nonspecific binding of 125 I-VIP was found in the region of the ectoplacental cone (Fig. 8, middle  and bottom) . In E9 and older embryos, both GTP-sensitive and GTP-insensitive binding sites were present.
Discussion
Our results characterize VIP expression and localization during early postimplantation mouse embryogenesis (E6 -E12). Previous work in the mouse showed that VIP regulates   FIG. 3 . ELISA of gestational days 9 and 17 maternal organs. VIP levels were not significantly different between E9 and E17 maternal organs (ovary, uterus, cervix/paracervix, intestine, cortex, hypothalamus, and spinal cord). The placenta is not completely formed at E9, thus placenta VIP levels were measured only at E17 .   FIG. 4 . ELISA was used to evaluate mouse maternal plasma VIP levels. No significant differences were present in samples from E6 -E12 conceptuses. Each sample contained pooled plasma from at least three mice (mean Ϯ SE).
FIG. 2.
Quantitative RT-PCR with a mimic primer revealed a significant increase of VIP mRNA in the decidua at E6 -E8. The location of the cross-over from predominately mimic product to message product was determined, and each sample was normalized to cyclophilin mRNA [also determined for each gestational day (GD)]. Data are presented as the percentage of VIP mRNA of GD 17. early postimplantation embryonic growth, at least in part, through action on binding sites localized to the primitive neuroepithelium and floor plate (4, 12) . This study shows that, although VIP mRNA was not apparent in the mouse embryo at this time, abundant VIP message was present in the decidua/trophoblast during early post implantation. This region was also found to contain abundant VIP-immunoreactive cells and dense VIP binding sites. VIP levels were significantly higher in E9, compared with E17 conceptuses, yet there were no significant differences in VIP levels in the maternal plasma or organs at these gestational ages. At E6, VIP binding sites were abundant in the mesometrial stroma (the area undergoing decidualization); however, the binding sites gradually decreased and reached low levels at the time of placenta formation (E10 -E11). By E11, after placenta formation, VIP mRNA became apparent in the embryo. Thus, during E9 -E11, the time during which VIP is known to play a role in growth regulation, both VIP binding sites and immunoreactivity are present, but VIP mRNA was not apparent in the embryo or yolk sac. However, in the decidua, VIP binding sites, mRNA, and immunoreactivity were abundant during this time period. The VIP immunoreactivity was localized to cells having T cell receptor markers CD3 and ␦. These findings suggest that the VIP, which is critical to embryonic growth, originates from maternal ␥␦ lymphocytes in the decidua.
In the mouse, transfer of VIP from mother to embryo has been demonstrated. Previous work from our laboratory has shown that 125 I-VIP, injected into the uterine vasculature, was found in the E10 mouse embryo (13) . The transfer apparently is rapid, because embryos were evaluated 15 min after injection. We have been unable to detect VIP mRNA in the mouse embryo at this crucial time; however, there are abundant binding sites in the floor plate and adjacent neuroepithelium (4). Our findings suggest that the source of VIP that acts during the postimplantation growth phase of the mouse embryo is maternal in origin. After implantation, decidual invasion, and placental formation, both maternal and embryonic tissues at the implantation site are undergoing rapid growth and differentiation. This region contains maternal blood cells coexisting with extraembryonic trophoblast cells. Whether the VIP produced in these cells is released and available to the embryo at this time would be difficult to determine. However, we have shown that the peptide is present, although not expressed by the embryo, during implantation. In addition, the time period between implantation and placental development, embryonic-maternal ex- change occurs primarily through the yolk sac surrounding the embryo. Several developmentally important regulatory factors and receptors are located in maternal decidual cells and embryonic trophoblast surrounding the parietal yolk sac, and these permit the transfer of nutrients to the visceral yolk sac (14) . In addition, as early as the 8 -10 somite stage (E8.5), vascularization of the yolk sac is continuous with the developing vasculature of the embryo. Functions of the surrounding trophoblast include transporting nutrients to the embryo, as well as transferring other molecules, including growth factors (14) . Transforming growth factor-␤1 (TGF-␤1) is one growth factor known FIG. 7 . In vitro autoradiogram of 125 I-VIP binding in E6 -E12 uteri. Beginning at E6, VIP binding sites were abundant in the mesometrial stroma, which is undergoing decidualization and remained dense through E7 and E8. By E9, these binding sites were much less apparent; and after E10, they were not evident. In the embryo, VIP binding sites were abundant in the floor plate (FP) and adjacent neuroepithelium from E9, the earliest age at which the neural tube was evident. to cross from mother to fetus, because embryos with a null mutation for TGF-␤1 are able to develop normally in utero because of transport of TGF-␤1 from the mother (15) . Evidence also exists that maternal PTH-related peptide, a factor with diverse actions in development, is transferred to the embryo during the early postimplantation period (16) .
Previous studies suggested that the regulation of growth by VIP occurs during a narrow window of development, beginning at least at E9 in the mouse and not extending beyond E11 (1, 2) . The current study demonstrates that VIPrelated measures such as mRNA and binding sites are undergoing dynamic changes during this time period. In addition, the end of this period, E11, is characterized by the appearance of VIP mRNA in the embryo and the disappearance of message and binding sites from the decidua/trophoblast. Furthermore, the placenta has formed from the trophoblast by E11 and becomes the major route of embryonic nutritional exchange. Taken together, these data suggest that, before E11, VIP secreted from maternal lymphocytes reaches the embryo to act at binding sites of the primitive neuroepithelium, to regulate growth. With the formation of the placenta, dependence on yolk sac nutrition decreases, VIP production ceases in the decidua/trophoblast, and the embryo begins to synthesize VIP.
In placental formation, the decidua is invaded by trophoblast, which results in a maternal response, with an invasion of lymphocytes. Previous work has demonstrated that lymphocytes are able to express VIP mRNA (8) and VIP receptors (9, 10) . Ten to 15% of all cells in the decidua are lymphocytes, and the number of ␥␦ T cells significantly increases in the uterus in pregnancy. The percentage of ␥␦ T cell lymphocytes at the maternal-fetal interface is 3-to 4-fold higher, compared with the spleen, and 2-fold higher than in nonpregnant uterus. Previous studies have demonstrated that all ␥␦ T lymphocytes at the maternal-fetal interface are maternally derived (7) . We have shown that these cells, T lymphocytes, which alone have the CD3 T cell receptor, are colocalized with VIP immunoreactivity. Furthermore, the population of lymphocytes specific to pregnancy, ␥␦ T cells, colocalize with VIP. These findings suggest that the source of VIP, at the critical time to regulate embryonic growth, is maternal lymphocytes in decidua, which are recruited during implantation. These findings are supported by the surge in VIP mRNA levels in the decidua at days 6 -8, the time before and around VIP regulation of embryonic growth.
The mechanism(s) through which VIP regulates embryonic growth are not well understood. Many functions of VIP occur indirectly, through the VIP-stimulated release of trophic factors from glial cells. For example, VIP is known to stimulate the release of activity-dependent neurotrophic factor (17) , protease nexin 1 (18) , and several cytokines (19) . In the developing embryo, VIP binds to receptors in the floor plate, which is composed of presumptive glial cells of the neural tube (20) ; and the bound VIP may stimulate the release of growth-regulatory factors from these cells. In addition, the VIP may stimulate cells in the decidua, to release growth regulatory peptides and/or cytokines.
An alternate hypothesis is that a VIP-like factor, synthesized by the embryo, is the endogenous growth regulator. The related peptide, PACAP with about 70% amino acid identity to VIP, binds with high affinity to the known VIP receptors, VIP 1 and VIP 2 (21) , and is present in the E9.5 mouse embryo (22) . However, previous work has shown that PACAP inhibits embryonic growth (23) , which suggests that PACAP is not the endogenous ligand acting at VIP receptors to induce embryonic growth.
Mouse embryos exhibited both GTP-sensitive and GTPinsensitive VIP binding sites. Because sensitivity to GTP is characteristic of cAMP-linked receptors (24) , the GTP-sensitive binding sites of the trophoblast may represent VIP binding to cloned adenyl cyclase-dependent VIP receptors, VIP 1 and VIP 2 (25) (26) (27) . The GTP-insensitive sites of the decidua/ trophoblast may represent VIP acting through adenyl cyclase-independent action implicated in the neurotrophic functions of VIP (28, 29) .
This study has not determined the anatomical site(s) where VIP mRNA is localized in the E11 mouse embryo; however, a highly sensitive in situ hybridization histochemistry technique has detected VIP mRNA in cells of the hindbrain of the E11 mouse (30) . In addition, we have found VIP mRNA in the E17 fetal mouse brain. In the rat, the earliest appearance of VIP mRNA was in peripheral embryonic tissues, including the sphenopalatine ganglia, as early as E16, with in situ hybridization (3), stellate ganglia at E14.5 (31) , and superior cervical ganglia at E15 (32) . VIP mRNA was not detected by RT-PCR in the E11 rat embryo (13) and was not apparent with in situ hybridization histochemistry in rat CNS tissues until birth (3) .
Some of our findings in the mouse are different from previous work in the rat. Similar to the experience with the rat, we were unable to demonstrate VIP mRNA in the mouse embryo during the time when VIP regulates embryonic growth (E9 -E11). However, VIP mRNA was demonstrated in the mouse trophoblast and decidua (E9 -E11), though not apparent in the rat at corresponding gestational ages. In addition, we did not find a peak of VIP in maternal mouse plasma, in contrast to the rat (where a peak of VIP in maternal serum had been observed at the corresponding gestational age of postimplantation growth regulation) (13) . The detection of increased VIP in the maternal serum of the rat may indicate spillover caused by greatly increased production, whereas the absence of a peak of VIP in maternal plasma in the mouse and human suggests that the increase in VIP is a more localized event and is limited to the decidua and extraembryonic membranes encasing the developing embryo. However, in both rat and mouse, during the critical time of postimplantation (when fetal growth is apparently regulated by VIP), the embryo does not express VIP message, thus both rely on nonembryonic sources.
Our findings suggest a dynamic interaction between the mother and the embryo, mediated by an extraembryonic neuropeptide, VIP, required for normal embryonic growth and development. The narrow window during which VIP exerts growth regulatory effects, the period between implantation and placentation, is the most vulnerable period of intrauterine development (5) . The maternal-embryonic dialog, so important to development during this period, is not well understood. Further characterization of factors, like VIP, involved in this period of development may define a critical phase in the regulation of coordinated embryonic development. Such insight has potential utility in diagnosis and treatment of conditions resulting from disregulated embryonic growth, such as microcephaly or growth restriction.
